

Francesco Di Raimondo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6103721/francesco-di-raimondo-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

343 papers	12,885 citations	53 h-index	106 g-index
358 ext. papers	14,863 ext. citations	4.9 avg, IF	5.39 L-index

#	Paper	IF	Citations
343	CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment.. <i>Oncogenesis</i> , 2022 , 11, 6	6.6	3
342	Immunological Subsets Characterization in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 819136	8.4	1
341	Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. <i>Diagnostics</i> , 2022 , 12, 1051	3.8	0
340	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2021 , 106, 291-294	6.6	7
339	CXCL12/CXCR4 Axis Drives Mitochondrial Trafficking in Tumor Myeloma Microenvironment. <i>Blood</i> , 2021 , 138, 2663-2663	2.2	
338	Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
337	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. <i>Haematologica</i> , 2021 , 106, 2345-2353	6.6	3
336	The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. <i>Annals of Hematology</i> , 2021 , 100, 1743-1753 ³		2
335	Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. <i>Frontiers in Oncology</i> , 2021 , 11, 624405	5.3	2
334	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021 , 11, 73	7	3
333	Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol. <i>European Journal of Haematology</i> , 2021 , 106, 831-835	3.8	3
332	Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. <i>Frontiers in Oncology</i> , 2021 , 11, 643490	5.3	2
331	TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. <i>American Journal of Hematology</i> , 2021 , 96, E306-E310	7.1	3
330	Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical Transcripts. <i>Frontiers in Pharmacology</i> , 2021 , 12, 669469	5.6	4
329	Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021 , 11, 684561	5.3	3
328	Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. <i>Leukemia</i> , 2021 , 35, 235-238	10.7	11
327	Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. <i>Haematologica</i> , 2021 , 106, 1559-1568	6.6	20

326	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. <i>European Journal of Haematology</i> , 2021 , 106, 493-499	3.8	1
325	A multicenter total therapy strategy for adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol. <i>Haematologica</i> , 2021 , 106, 1828-1838	6.6	8
324	Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. <i>American Journal of Hematology</i> , 2021 , 96, E168-E171	7.1	5
323	Post-transplant consolidation based on combination of lenalidomide and proteasome inhibitors in multiple myeloma. <i>Panminerva Medica</i> , 2021 , 63, 13-20	2	0
322	Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents. <i>Panminerva Medica</i> , 2021 , 63, 1-6	2	2
321	Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2021 , 11, 684621	5.3	1
320	A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic. <i>Diagnostics</i> , 2021 , 11,	3.8	1
319	The first description of a singular case of synchronous chronic myelomonocytic leukemia and diffuse large b-cell lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e03817	0.7	0
318	ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. <i>Anticancer Research</i> , 2020 , 40, 2457-2465	2.3	13
317	Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells. <i>Biomolecules</i> , 2020 , 10,	5.9	17
316	Optimal Response in a Patient With CML Expressing E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report. <i>In Vivo</i> , 2020 , 34, 1481-1486	2.3	1
315	The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data. <i>European Journal of Haematology</i> , 2020 , 105, 3-15	3.8	6
314	Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions. <i>World Journal of Emergency Surgery</i> , 2020 , 15, 17	9.2	3
313	Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study. <i>European Journal of Haematology</i> , 2020 , 104, 581-587	3.8	6
312	Targeting BCL-2 as a Therapeutic Strategy for Primary -positive B-ALL Cells. <i>In Vivo</i> , 2020 , 34, 511-516	2.3	4
311	Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells. <i>Cancers</i> , 2020 , 12,	6.6	13
310	Serum free light chains and multiple myeloma: Is it time to extend their application?. <i>Clinical Case Reports (discontinued)</i> , 2020 , 8, 617-624	0.7	2
309	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020 , 135, 1244-1254	2.2	18

308	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020 , 136, 47-48	2.2	
307	Lactate As Metabolic Link between Cancer Cells and Tumor Microenvironment in Myelofibrosis Patients. <i>Blood</i> , 2020 , 136, 26-26	2.2	
306	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. <i>Blood</i> , 2020 , 136, 45-46	2.2	
305	An Integrative Unbiased Global Analysis of the Metabolic Adaptive Response to Tryptophan Deprivation in Classical Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 26-27	2.2	
304	The Heme Oxygenase-1/Carbon Monoxide Pathway Activates TLR4 Signaling Promoting Bortezomib Resistance in Multiple Myeloma Cells. <i>Blood</i> , 2020 , 136, 13-14	2.2	
303	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020 , 136, 54-55	2.2	
302	DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 53-54	2.2	6
301	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020 , 126, 1243-1252	6.4	51
300	How we manage smoldering multiple myeloma. <i>Hematology Reports</i> , 2020 , 12, 8951	0.9	0
299	Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib. <i>Redox Biology</i> , 2020 , 36, 101611	11.3	14
298	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. <i>Lancet Haematology</i> , 2020 , 7, e861-e873	14.6	19
297	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial. <i>Cancer Medicine</i> , 2020 , 9, 8735-8746	4.8	6
296	Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. <i>Anticancer Research</i> , 2020 , 40, 5313-5317	2.3	2
295	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. <i>Cancer Medicine</i> , 2020 , 9, 8468-8479	4.8	8
294	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. <i>Blood Cancer Journal</i> , 2020 , 10, 92	7	5
293	A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
292	Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. <i>Frontiers in Oncology</i> , 2020 , 10, 604143	5.3	13
291	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. <i>Haematologica</i> , 2020 , 105, 193-200	6.6	12

290	In Ph+BCR-ABL1 acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020 , 34, 929-931	10.7	2
289	Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. <i>Blood</i> , 2020 , 135, 534-541	2.2	37
288	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1613-1620	6.6	6
287	Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib. <i>In Vivo</i> , 2019 , 33, 1593-1598	2.3	6
286	TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma. <i>Cell Death and Disease</i> , 2019 , 10, 704	9.8	13
285	Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	23
284	Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	12
283	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2019 , 20, 781-794	21.7	150
282	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6	6
281	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019 , 33, 2111-2115	10.7	10
280	Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report. <i>Acta Haematologica</i> , 2019 , 141, 261-267	2.7	8
279	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. <i>Cancer Medicine</i> , 2019 , 8, 2041-2055	4.8	40
278	Once-weekly twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019 , 104, 1640-1647	6.6	16
277	Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2019 , 185, 468-479	4.5	11
276	Chk1 Inhibition Restores Inotuzumab Ozogamicin Cytotoxicity in CD22-Positive Cells Expressing Mutant p53. <i>Frontiers in Oncology</i> , 2019 , 9, 57	5.3	14
275	Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib. <i>Molecular Neurobiology</i> , 2019 , 56, 1451-1460	6.2	20
274	Unusual Karyotype in Acute Myelomonocytic Leukemia: A Case Report. <i>Anticancer Research</i> , 2019 , 39, 4329-4332	2.3	1
273	Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 fusion transcript: A case report. <i>Oncology Letters</i> , 2019 , 18, 2648-2653	2.6	5

272	Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors. <i>Frontiers in Oncology</i> , 2019 , 9, 764	5.3	6
271	Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	13
270	Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	14
269	Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Fusion Transcript: A Case Report. <i>Anticancer Research</i> , 2019 , 39, 3949-3954	2.3	8
268	Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	4
267	A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?. <i>Clinical Case Reports (discontinued)</i> , 2019 , 7, 1629-1636	0.7	2
266	Management of Chronic Myeloid Leukemia in Advanced Phase. <i>Frontiers in Oncology</i> , 2019 , 9, 1132	5.3	26
265	Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	10
264	Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. <i>Blood Reviews</i> , 2019 , 34, 84-94	11.1	19
263	VTE Incidence in RRMM Patients Treated with NOVEL Agents: A Monocentric Real Life Experience. <i>Blood</i> , 2019 , 134, 4972-4972	2.2	
262	Inhibition of TLR4 Signaling Affects Mitochondrial Fitness Overcoming Bortezomib Resistance in Myeloma Plasma Cells. <i>Blood</i> , 2019 , 134, 3073-3073	2.2	
261	Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS. <i>Blood</i> , 2019 , 134, 4868-4868	2.2	
260	Ixazomib Modulates Bone Remodeling and Activates Sonic Hedgehog Pathways. <i>Blood</i> , 2019 , 134, 4345-4345	2.2	
259	Detection and Clinical Implications of a Novel E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform. <i>Anticancer Research</i> , 2019 , 39, 6965-6971	2.3	4
258	Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). <i>Annals of Hematology</i> , 2019 , 98, 361-367	3	1
257	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	40	283
256	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1357-1366	4.9	6
255	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018 , 32, 1869-1873	10.7	8

254	Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. <i>Annals of Hematology</i> , 2018 , 97, 1009-1018	3	28
253	PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. <i>Expert Review of Molecular Diagnostics</i> , 2018 , 18, 675-683	3.8	37
252	NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types. <i>British Journal of Haematology</i> , 2018 , 182, 597-602	4.5	15
251	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. <i>European Journal of Haematology</i> , 2018 , 101, 703	3.8	5
250	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018 , 93, E216-E219	7.1	9
249	Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. <i>Molecular Cancer</i> , 2018 , 17, 56	42.1	39
248	Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2018 , 4, 1389-1397	13.4	48
247	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018 , 55, 248-255	4	13
246	Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 1070-1080	5.6	20
245	Tryptophan Deprivation Promotes an Adaptive Response and Contributes to Bioenergetics in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 4511-4511	2.2	1
244	Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes. <i>Blood</i> , 2018 , 132, 125-125	2.2	9
243	Analysis of Metabolic Parameters Coming from Basal and Interim PET in Hodgkin Lymphoma. <i>Current Medical Imaging</i> , 2018 , 14, 533-544	1.2	3
242	Impact of Cumulative Dose of Carfilzomib in Combination with Lenalidomide and Desamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real Life Survey of the Sicilian Myeloma Network. <i>Blood</i> , 2018 , 132, 5636-5636	2.2	
241	Role of TLR4 in the Activation of a Pro-Tumor Phenotype of Mesenchymal Stromal Cells in Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1892-1892	2.2	
240	Elotuzumab, Lenalidomide, and Dexamethasone (EloRd) As Salvage Therapy for Patients with Multiple Myeloma: Italian, Multicenter, Retrospective Clinical Experience with 180 Cases Outside of Controlled Clinical Trials. <i>Blood</i> , 2018 , 132, 2023-2023	2.2	
239	Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Myelofibrosis Patients Treated with Ruxolitinib: A Multi-Center Experience. <i>Blood</i> , 2018 , 132, 4303-4303	2.2	1
238	Safety in Patients with Multiple Myeloma Treated with Pomalidomide in a Real-World Setting According to Last Prior Treatment: A European Post-Authorization Safety Study. <i>Blood</i> , 2018 , 132, 3286-3286	2.2	3286
237	Long Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Real Life Experience. <i>Blood</i> , 2018 , 132, 5669-5669	2.2	

236	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) and Lymphocyte to Monocyte Ratio (LMR) in Newly Diagnosed Advanced-Stage Hodgkin Lymphoma Patients Treated up-Front with a PET-2 Risk Adapted Protocol. <i>Blood</i> , 2018 , 132, 2934-2934	2.2	
235	Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by PhN Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. <i>Chemotherapy</i> , 2018 , 63, 220-224	3.2	16
234	Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines. <i>European Journal of Medicinal Chemistry</i> , 2018 , 158, 937-950	6.8	30
233	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, e401-e419	2	37
232	Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. <i>Future Oncology</i> , 2017 , 13, 3-6	3.6	5
231	The Heme Oxygenase System in Hematological Malignancies. <i>Antioxidants and Redox Signaling</i> , 2017 , 27, 363-377	8.4	25
230	Mutations in the 3'Untranslated region of are associated with low CD20 expression levels chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e305-e309	6.6	11
229	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017 , 92, 244-250	7.1	14
228	Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study. <i>Leukemia Research</i> , 2017 , 62, 77-83	2.7	13
227	High Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib. <i>Clinical Cancer Research</i> , 2017 , 23, 7189-7198	12.9	29
226	Mutational status of is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e443-e446	6.6	8
225	A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. <i>American Journal of Hematology</i> , 2017 , 92, 82-87	7.1	22
224	The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents. <i>Blood Cancer Journal</i> , 2017 , 7, 649	7	20
223	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. <i>Oncotarget</i> , 2017 , 8, 79073-79086	3.3	38
222	CHI3L1 nuclear localization in monocyte derived dendritic cells. <i>Immunobiology</i> , 2016 , 221, 347-56	3.4	22
221	Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. <i>Leukemia and Lymphoma</i> , 2016 , 57, 116-9	1.9	9
220	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016 , 30, 513-7	10.7	2
219	Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. <i>Oncotarget</i> , 2016 , 7, 28868-80	3.3	45

218	Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. <i>Infectious Agents and Cancer</i> , 2016 , 11, 27	3.5	25
217	Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report. <i>Journal of Medical Case Reports</i> , 2016 , 10, 315	1.2	2
216	Elution time changes due to anomalous DEP effects in microchannels under uniform and non-uniform electric fields. <i>Sensing and Bio-Sensing Research</i> , 2016 , 8, 59-64	3.3	1
215	The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 26	22.4	7
214	Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. <i>Expert Review of Anticancer Therapy</i> , 2016 , 16, 273-8	3.5	39
213	European Post-Approval Safety Study (Registry) of Relapsed/Refractory Multiple Myeloma (RRMM): Safety of Patients Treated with Pomalidomide. <i>Blood</i> , 2016 , 128, 5680-5680	2.2	1
212	Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8000-8000	2.2	43
211	The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma. <i>Oncotarget</i> , 2016 , 7, 67333-67346	3.3	16
210	Contribution of High-Density Neutrophils to Multiple Myeloma Microenvironment Dysregulation. <i>Blood</i> , 2016 , 128, 5643-5643	2.2	
209	The B-Cell Receptor Signaling Inhibitor Molecules CD305 and CD307b Are Markers of Favorable Prognosis in Chronic Lymphocytic Leukemia with Both Mutated and Unmutated IGHV Gene Status. <i>Blood</i> , 2016 , 128, 4358-4358	2.2	
208	Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). <i>Oncotarget</i> , 2016 , 7, 85764-85775	3.3	56
207	Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM). <i>Nutrients</i> , 2016 , 8,	6.7	19
206	Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients. <i>PLoS ONE</i> , 2016 , 11, e0158392	3.7	18
205	Erythrocytapheresis is a valid and safe therapeutic option in dysmetabolic iron overload syndrome. <i>Journal of Clinical Apheresis</i> , 2016 , 31, 443-7	3.2	
204	Analysis of the role of elution buffers on the separation capabilities of dielectrophoretic devices. <i>Sensing and Bio-Sensing Research</i> , 2016 , 7, 162-167	3.3	3
203	Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016 , 101, e196-9	6.6	13
202	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. <i>European Journal of Cancer</i> , 2016 , 60, 154-65	7.5	16
201	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016 , 128, 497-503	2.2	117

200	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4015-4022	2.2	49
199	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016 , 91, 1090-1095	7.1	43
198	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <i>European Journal of Haematology</i> , 2016 , 96, 36-45	3.8	6
197	Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. <i>Blood</i> , 2015 , 125, 3455-65	2.2	98
196	The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. <i>Leukemia</i> , 2015 , 29, 1336-43	10.7	126
195	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3150-8	1.9	17
194	Absolute lymphocyte count is unrelated to overall survival in newly diagnosed elderly patients with multiple myeloma treated with immunomodulatory drugs. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1507-9	1.9	5
193	Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. <i>Annals of Hematology</i> , 2015 , 94, 1875-83	3	32
192	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3459-66	2.2	104
191	Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. <i>British Journal of Haematology</i> , 2015 , 168, 689-700	4.5	57
190	Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. <i>British Journal of Haematology</i> , 2015 , 168, 455-9	4.5	7
189	Percutaneous transluminal aortic valve implantation for severe aortic valve stenosis in a patient with severe haemophilia A. <i>Haemophilia</i> , 2015 , 21, e500-3	3.3	
188	Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. <i>Frontiers in Pharmacology</i> , 2015 , 6, 226	5.6	15
187	Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. <i>Oncotarget</i> , 2015 , 6, 17543-58	3.3	45
186	miR-155 regulative network in FLT3 mutated acute myeloid leukemia. <i>Leukemia Research</i> , 2015 , 39, 883-26	2.6	15
185	Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation. <i>Inflammation</i> , 2015 , 38, 2082-91	5.1	17
184	Differences among young adults, adults and elderly chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2015 , 26, 185-192	10.3	48
183	Treatment and Outcome Analysis of 2,904 Patients from the EUTOS Population Based Registry. <i>Blood</i> , 2015 , 126, 2780-2780	2.2	1

182	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015 , 126, 4225-4225	2.2	3
181	Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. <i>PLoS ONE</i> , 2015 , 10, e0118801	3.7	12
180	Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myeloid Leukemia: Comparison with FISH and PCR Techniques. <i>PLoS ONE</i> , 2015 , 10, e0130360	3.7	4
179	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2015 , 6, 19102-17	3.3	13
178	Rare gastrointestinal lymphomas: The endoscopic investigation. <i>World Journal of Gastrointestinal Endoscopy</i> , 2015 , 7, 928-49	2.2	12
177	Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. <i>Turkish Journal of Haematology</i> , 2015 , 32, 206-12	0.9	3
176	Role of Nuclear Heme Oxygenase-1 in Bortezomib Induced Cell Death. <i>FASEB Journal</i> , 2015 , 29, 897.2	0.9	
175	Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014 , 89, 480-6	7.1	86
174	High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2014 , 165, 629-39	4.5	44
173	IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. <i>Carcinogenesis</i> , 2014 , 35, 1132-43	4.6	25
172	Determination of chitinases family during osteoclastogenesis. <i>Bone</i> , 2014 , 61, 55-63	4.7	40
171	Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. <i>Bone Marrow Transplantation</i> , 2014 , 49, 485-91	4.4	10
170	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. <i>Journal of Clinical Oncology</i> , 2014 , 32, 634-40	2.2	171
169	Autologous transplantation and maintenance therapy in multiple myeloma. <i>New England Journal of Medicine</i> , 2014 , 371, 895-905	59.2	539
168	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 181-9	7	4
167	Prognostic assessment and treatment of primary gastric lymphomas: how endoscopic ultrasonography can help in tailoring patient management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014 , 14, 179-85	2	15
166	Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. <i>PLoS ONE</i> , 2014 , 9, e101848	3.7	55
165	Salvage therapy of multiple myeloma: the new generation drugs. <i>BioMed Research International</i> , 2014 , 2014, 456037	3	16

164	Immunological deregulation in classic hodgkin lymphoma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014 , 6, e2014039	3.2	13
163	Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up. <i>World Journal of Gastroenterology</i> , 2014 , 20, 12993-3005	5.6	30
162	Low-dose lenalidomide plus cytarabine induce complete remission that can be predicted by genetic profiling in elderly acute myeloid leukemia patients. <i>Leukemia</i> , 2014 , 28, 967-70	10.7	12
161	Immunological dysregulation in multiple myeloma microenvironment. <i>BioMed Research International</i> , 2014 , 2014, 198539	3	83
160	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <i>American Journal of Hematology</i> , 2014 , 89, 743-50	7.1	13
159	A snapshot of asparaginase-induced liver insufficiency. <i>European Journal of Haematology</i> , 2014 , 92, 271-3	3.8	1
158	Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients. <i>European Journal of Haematology</i> , 2014 , 93, 207-13	3.8	11
157	Percutaneous transluminal angioplasty and stent implantation for aortic coarctation in haemophilia A patient with high-titre factor VIII inhibitors. <i>Haemophilia</i> , 2014 , 20, e336-8	3.3	1
156	BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein. <i>FASEB Journal</i> , 2014 , 28, 1221-36	0.9	25
155	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014 , 28, 222-5	10.7	63
154	Management of Venous Thromboembolism (VTE) in Patients with Acute Leukemia: Results from a Multicenter Study. <i>Blood</i> , 2014 , 124, 3688-3688	2.2	1
153	SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. <i>BMC Cancer</i> , 2013 , 13, 60	4.8	14
152	Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. <i>Annals of Hematology</i> , 2013 , 92, 1271-80	3	3
151	Standard therapies versus novel therapies in Hodgkin lymphoma. <i>Immunology Letters</i> , 2013 , 155, 56-9	4.1	9
150	CD200 expression in patients with Multiple Myeloma: another piece of the puzzle. <i>Leukemia Research</i> , 2013 , 37, 1616-21	2.7	15
149	Treatment of elderly patients with chronic lymphocytic leukemia: an unmet clinical need. <i>Expert Review of Hematology</i> , 2013 , 6, 441-9	2.8	4
148	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study. <i>American Journal of Hematology</i> , 2013 , 88, 539-44	7.1	7
147	Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. <i>American Journal of Hematology</i> , 2013 , 88, 16-23	7.1	48

146	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013 , 88, 24-31	7.1	21
145	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: results of a comparative analysis. <i>Leukemia Research</i> , 2013 , 37, 943-7	2.7	7
144	Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. <i>Clinical Cancer Research</i> , 2013 , 19, 5890-900	12.9	50
143	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 83	22.4	14
142	Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1085-98	6.1	48
141	Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients. <i>Current Cancer Therapy Reviews</i> , 2013 , 9, 1-7	0.4	
140	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013 , 24, 2108-12	10.3	104
139	Bortezomib for the treatment of previously untreated multiple myeloma. <i>Immunotherapy</i> , 2013 , 5, 327-528	5.28	22
138	Intravenous injection of bortezomib, melphalan and dexamethasone in refractory and relapsed multiple myeloma. <i>Annals of Oncology</i> , 2013 , 24, 1038-44	10.3	10
137	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2013 , 119, 1177-85	6.4	12
136	Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. <i>Clinical Cancer Research</i> , 2013 , 19, 3130-42	12.9	76
135	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 4902-5	2.2	94
134	Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. <i>Blood</i> , 2013 , 122, 3759-66	2.2	63
133	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. <i>Blood</i> , 2013 , 122, 3317-21	2.2	36
132	Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. <i>Haematologica</i> , 2013 , 98, 1702-10	6.6	87
131	Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. <i>Current Pharmaceutical Design</i> , 2013 , 19, 2765-70	3.3	70
130	High BCR-ABL/GUSIS Levels At Diagnosis Are Associated With Unfavorable Responses To Imatinib. <i>Blood</i> , 2013 , 122, 1495-1495	2.2	4
129	Neutrophils Of Multiple Myeloma Are Dysfunctional and Immunosuppressive. <i>Blood</i> , 2013 , 122, 3138-3138	3.38	3

128	Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 4383-4383	2.2	1
127	Long-Term Health Related Quality Of Life and Symptom Burden In Patients With Acute Promyelocytic Leukemia Treated With All-Trans Retinoic Acid (ATRA) and Chemotherapy. <i>Blood</i> , 2013 , 122, 770-770	2.2	2
126	Incidence and Management Of Venous Thrombosis In Acute Leukemia: A Multicenter Study. <i>Blood</i> , 2013 , 122, 3890-3890	2.2	
125	Low-Dose Lenalidomide Plus Low Dose Cytarabine Induce Complete Remission That Can Be Predicted By Genetic Profiling In Very Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013 , 122, 496-496 ²	2.2	
124	Myeloid Derived Suppressor Cells (MDSCs) Are Increased and Exert Immunosuppressive Activity In CML Patients At Diagnosis. <i>Blood</i> , 2013 , 122, 2711-2711	2.2	
123	Stereotyped Subset #4 In Chronic Lymphocytic Leukemia Is Associated With Distinct Gene and MicroRNA Transcriptional Profile. <i>Blood</i> , 2013 , 122, 1616-1616	2.2	
122	Myeloid Cells Exert Immunosuppressive Activity and Have Prognostic Value In Hodgkin Lymphoma. <i>Blood</i> , 2013 , 122, 4238-4238	2.2	
121	Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients. <i>Blood</i> , 2013 , 122, 3126-3126	2.2	1
120	A Randomized Open-Label Study To Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE). <i>Blood</i> , 2013 , 122, 3967-3967 ²	2.2	
119	Primary plasma cell leukemia in the era of new drugs: has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 82, 141-9	7	17
118	Towards a need to a "biological Sokal risk" in the era of tyrosine kinase inhibitors in choosing front-line therapy in chronic myeloid leukemia. <i>Leukemia Research</i> , 2012 , 36, 803	2.7	3
117	Intrasomatic injection of corticosteroid followed by vertebroplasty increases early pain relief rather than vertebroplasty alone in vertebral bone neoplasms: preliminary experience. <i>Skeletal Radiology</i> , 2012 , 41, 459-64	2.7	7
116	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012 , 119, 933-9; quiz 1093	2.2	212
115	Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients. <i>British Journal of Haematology</i> , 2012 , 159, 237-40 ⁵	2.2	12
114	Treatment of older patients with mantle-cell lymphoma. <i>New England Journal of Medicine</i> , 2012 , 367, 520-31	59.2	368
113	Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment. <i>Leukemia Research</i> , 2012 , 36, 1208-9	2.7	3
112	Bone turnover markers in patients with type 1 Gaucher disease. <i>Hematology Reports</i> , 2012 , 4, e21	0.9	17
111	Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. <i>Hematological Oncology</i> , 2012 , 30, 180-5	1.3	10

110	Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors. <i>Hematological Oncology</i> , 2012 , 30, 27-33	1.3	23
109	Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. <i>International Journal of Cancer</i> , 2012 , 131, 2197-203	7.5	58
108	Clinical relevance of the association of interferon alfa to imatinib in chronic myeloid leukemia therapy. <i>International Journal of Hematology</i> , 2012 , 96, 142-3	2.3	1
107	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). <i>British Journal of Haematology</i> , 2012 , 156, 205-12	4.5	55
106	Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia. <i>Acta Haematologica</i> , 2012 , 127, 7-9	2.7	16
105	Diagnosis of blastic phase of chronic myeloid leukemia. <i>Acta Haematologica</i> , 2012 , 127, 198	2.7	
104	Infliximab therapy in hematologic malignancies: handle with care. <i>Haematologica</i> , 2012 , 97, e26; author reply e27	6.6	0
103	Early interim 2-(1)fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to peripheral blood lymphocyte/monocyte ratio at diagnosis in classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012 , 97, e21-3; author reply e24	6.6	18
102	Treating Ph+ Acute Lymphoblastic Leukemia (ALL) in the Elderly: The Sequence of Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imatinib) Does Not Prevent Mutations and Relapse.. <i>Blood</i> , 2012 , 120, 2601-2601	2.2	4
101	High BCR-ABL Levels At Diagnosis Are Associated with Unfavorable Responses to Imatinib Mesylate.. <i>Blood</i> , 2012 , 120, 2790-2790	2.2	3
100	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. <i>Blood</i> , 2012 , 120, 930-930	2.2	
99	Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients. <i>Clinical Drug Investigation</i> , 2011 , 31, 745-58	3.2	15
98	Consequences of metaphase II oocyte cryopreservation on mRNA content. <i>Cryobiology</i> , 2011 , 62, 130-4	2.7	42
97	Double CEBPE-IGH rearrangement due to chromosome duplication and cryptic insertion in an adult with B-cell acute lymphoblastic leukemia. <i>Cancer Genetics</i> , 2011 , 204, 563-8	2.3	2
96	Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. <i>Blood</i> , 2011 , 118, 4554-60	2.2	175
95	Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. <i>Journal of Clinical Virology</i> , 2011 , 52, 284-7	14.5	5
94	Imatinib discontinuation: realistic for patients with chronic myeloid leukaemia achieving complete molecular remission?. <i>Lancet Oncology</i> , 2011 , 12, 118	21.7	3
93	Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. <i>PLoS ONE</i> , 2011 , 6, e24313	3.7	35

92	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011 , 117, 4716-25	2.2	147
91	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011 , 152, 551-60	4.5	115
90	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. <i>British Journal of Haematology</i> , 2011 , 154, 564-8	4.5	22
89	Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. <i>European Journal of Haematology</i> , 2011 , 86, 216-25	3.8	6
88	Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. <i>Blood</i> , 2011 , 118, 6153-63	2.2	191
87	Vertebroplasty in multiple myeloma with osteolysis or fracture of the posterior vertebral wall. Usefulness of a delayed cement injection. <i>Skeletal Radiology</i> , 2011 , 40, 913-9	2.7	18
86	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the MLL/ENL fusion gene. <i>American Journal of Hematology</i> , 2011 , 86, 993-7	7.1	4
85	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011 , 50, 633-43	5	57
84	BRAF mutations in hairy-cell leukemia. <i>New England Journal of Medicine</i> , 2011 , 364, 2305-15	59.2	791
83	NF-B localization in multiple myeloma plasma cells and mesenchymal cells. <i>Leukemia Research</i> , 2011 , 35, 52-60	2.7	14
82	Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. <i>Blood</i> , 2011 , 118, 5759-66	2.2	31
81	BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. <i>Acta Haematologica</i> , 2011 , 126, 205-10	2.7	28
80	Rituximab Plus Chlorambucil As Initial Treatment for Elderly Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Pre-Treatment Biological Characteristics and Gene Expression Patterns on Response to Treatment. <i>Blood</i> , 2011 , 118, 294-294	2.2	4
79	Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY. <i>Blood</i> , 2011 , 118, 2837-2837	2.2	
78	Histone Deacetylase Inhibitors Induce Cell Growth Inhibition and Apoptosis in NPM1-Mutated AML Cells: A Possible Role for Epigenetic Therapies in AML Carrying NPM1 Gene Mutations. <i>Blood</i> , 2011 , 118, 2621-2621	2.2	
77	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. <i>Blood</i> , 2011 , 118, 1682-1682	2.2	
76	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. <i>Blood</i> , 2011 , 118, 786-786	2.2	
75	Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2010 , 51, 554-7	1.9	1

74	Utility of flow cytometry as a screening tool for transplant donors for chronic lymphocytic leukemia. <i>Acta Haematologica</i> , 2010 , 123, 235-6	2.7	
73	Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia. <i>Acta Haematologica</i> , 2010 , 124, 103-4	2.7	
72	V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. <i>Journal of Immunology</i> , 2010 , 184, 3260-8	5.3	117
71	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. <i>Lancet, The</i> , 2010 , 376, 2075-85	4.0	672
70	Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. <i>Acta Oncologica</i> , 2010 , 49, 506-8	3.2	37
69	CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. <i>Blood</i> , 2010 , 116, 3907-22	2.2	83
68	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010 , 116, 3171-9	2.2	249
67	Sacroplasty for local or massive localization of multiple myeloma. <i>CardioVascular and Interventional Radiology</i> , 2010 , 33, 1270-7	2.7	20
66	Amyloid in bone marrow smears of patients affected by multiple myeloma. <i>Annals of Hematology</i> , 2010 , 89, 469-74	3	40
65	Pleural presentation of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: a case report and a review of the literature. <i>International Journal of Hematology</i> , 2010 , 92, 369-73	2.3	15
64	Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. <i>European Journal of Haematology</i> , 2010 , 84, 223-8	3.8	62
63	Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. <i>American Journal of Hematology</i> , 2010 , 85, 375-7	7.1	6
62	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010 , 34, e217-8	2.7	2
61	Clonal selection of 11q CN-LOH and CBL gene mutation in a serially studied patient during MDS progression to AML. <i>Leukemia Research</i> , 2010 , 34, 1539-42	2.7	30
60	BCR-ABLIS Expression at Diagnosis and After 3 or 6 Months of Treatment Predicts CML Response to IMATINIB Therapy.. <i>Blood</i> , 2010 , 116, 3426-3426	2.2	1
59	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥5 years) Ph+ CML Patients [EudraCT Number 2007005102-42, ClinicalTrials.Gov NCT 00858806.. <i>Blood</i> , 2010 , 116, 3412-3412	2.2	
58	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. <i>Blood</i> , 2010 , 116, 2273-2273	2.2	
57	Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5001-7	2.2	42

56	Uncommon long-term survival in a patient with chronic myeloid leukemia. <i>Acta Oncologica</i> , 2009 , 48, 1215-6	3.2	5
55	Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5397-403	2.2	140
54	Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4555-62	2.2	483
53	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. <i>European Journal of Haematology</i> , 2009 , 82, 93-105	3.8	17
52	Effects of imatinib mesylate in osteoblastogenesis. <i>Experimental Hematology</i> , 2009 , 37, 461-8	3.1	37
51	Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2009 , 88, 967-71	3	26
50	The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma. <i>BMC Medical Genomics</i> , 2009 , 2, 20	3.7	18
49	CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009 , 33, 1212-6	2.7	106
48	Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. <i>Haematologica</i> , 2009 , 94, 1391-8	6.6	82
47	First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. <i>Current Drug Targets</i> , 2009 , 10, 906-22	3	6
46	Variation of T-Reg and CD 200+ T- Lymphocytes After in Vitro Treatment with Active Drugs against CLL. <i>Blood</i> , 2009 , 114, 1239-1239	2.2	
45	Myeloid-Derived Suppressor Cells in Patients with Hodgkin Lymphoma. <i>Blood</i> , 2009 , 114, 3662-3662	2.2	
44	Results of Imatinib Dose Escalation After 36 Months of Follow-up in Chronic Myeloid Leukemia Patients with Failure or Sub-Optimal Response According to 2006 European Leukemia Net (ELN) Criteria. <i>Blood</i> , 2009 , 114, 3302-3302	2.2	
43	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008 , 143, 681-9	4.5	50
42	Role of thalidomide in previously untreated patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 1569-80	3.5	4
41	Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia. <i>Acta Haematologica</i> , 2008 , 120, 19-30	2.7	24
40	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4004-13	2.2	200
39	Treatment of newly diagnosed multiple myeloma. <i>Current Hematologic Malignancy Reports</i> , 2008 , 3, 107-14	4.4	

38	Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis. <i>Leukemia Research</i> , 2008 , 32, 673-4	2.7	13
37	Role of New Tyrosine Kinase Inhibitors in Osteoblastogenesis. <i>Blood</i> , 2008 , 112, 4751-4751	2.2	
36	Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4459-65	2.2	276
35	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
34	Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2434-41	2.2	289
33	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2007 , 109, 5473-6	2.2	42
32	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. <i>Blood</i> , 2007 , 109, 3676-8	2.2	277
31	CD200 Expression May Help in Differential Diagnosis between Mantle Cell Lymphoma (MCL) and B-Cell Chronic Lymphocytic Leukemia (B-CLL).. <i>Blood</i> , 2007 , 110, 4672-4672	2.2	1
30	Role of Imatinib Mesylate in Osteoblastogenesis.. <i>Blood</i> , 2007 , 110, 1928-1928	2.2	
29	Salvage Therapy with Intravenous Bortezomib, Melphalan and Dexamethasone in Previously Treated Myeloma Patients.. <i>Blood</i> , 2007 , 110, 2728-2728	2.2	
28	Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 4307-4307	2.2	
27	Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. <i>Blood</i> , 2006 , 108, 4146-55	2.2	82
26	Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. <i>Blood</i> , 2006 , 108, 3951-2	2.2	48
25	In Vitro Cytotoxicity of Alemtuzumab on B-CLL Cells: Differential Effect on B and T Lymphocytes.. <i>Blood</i> , 2006 , 108, 4981-4981	2.2	
24	Hypoxia Induces Imatinib Resistance in CML Cell Lines.. <i>Blood</i> , 2006 , 108, 4387-4387	2.2	
23	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. <i>Blood</i> , 2005 , 105, 3434-41	2.2	161
22	Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. <i>Journal of Experimental Medicine</i> , 2004 , 199, 59-68	16.6	161
21	Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. <i>Leukemia Research</i> , 2004 , 28, 469-77	2.7	50

20	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. <i>Blood</i> , 2003 , 102, 2014-20	2.2	35
19	Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. <i>Cancer</i> , 2003 , 97, 114-20	6.4	72
18	Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. <i>British Journal of Haematology</i> , 2003 , 120, 405-12	4.5	24
17	E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. <i>British Journal of Haematology</i> , 2003 , 120, 484-7	4.5	54
16	Multidrug resistance mechanisms in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 774-80	4.5	32
15	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. <i>Blood</i> , 2002 , 99, 863-71	2.2	289
14	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 100, 974-81	2.2	92
13	Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas. <i>Leukemia and Lymphoma</i> , 2002 , 43, 2319-24	1.9	4
12	Lymphoma of the cecum: a case report. <i>International Surgery</i> , 2002 , 87, 12-4	0.1	4
11	Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319. <i>British Journal of Haematology</i> , 2001 , 114, 230-2	4.5	10
10	Angiogenesis in chronic myeloproliferative diseases. <i>Acta Haematologica</i> , 2001 , 106, 177-83	2.7	53
9	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). <i>The Hematology Journal</i> , 2001 , 2, 54-60		4
8	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2000 , 109, 788-93	4.5	26
7	In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1998 , 102, 528-31	4.5	11
6	Evaluation of Taxol cytotoxicity on B-CLL cells in vitro. <i>Leukemia and Lymphoma</i> , 1997 , 26, 115-9	1.9	9
5	In vitro sensitivity of B-CLL cells to fludarabine and interferons. <i>Leukemia and Lymphoma</i> , 1995 , 17, 449-53		6
4	Hypereosinophilia and subcutaneous heparin. <i>Lancet, The</i> , 1993 , 342, 1371	4.0	6
3	Trisomy 8 in Philadelphia chromosome (Ph1)-negative cells in the course of Ph1-positive chronic myelocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 1992 , 4, 269-70	5	26

- | | | |
|---|---|-----|
| 2 | A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. <i>European Journal of Cancer & Clinical Oncology</i> , 1991 , 27, 750-5 | 84 |
| 1 | Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment. <i>Acta Haematologica</i> , 1986 , 75, 125-6 | 2.7 |